ClinicalTrials.gg
Not yet recruitingNCT07923474Updated Nov 6, 2026

Virtual Reality Multidomain Training for Older Adults With Cognitive Frailty

An interventional study of Virtual Reality Multidomain Training and Multidomain Health Education in Cognitive Frailty, sponsored by Zheng Li. Not yet recruiting. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Zheng Li · Not applicable, Interventional, and Supportive care

Updated Nov 6, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

This randomized controlled trial will evaluate the effects of a virtual reality (VR) multidomain intervention on cognitive function in older adults with cognitive frailty and explore its underlying mechanisms.

Participants will receive either supervised VR training twice weekly for 8 weeks or multidomain health education. The VR program combines cognitive training, physical exercise, nutrition education, and emotional support.

Cognitive function, physical function, emotional symptoms, and nutritional status will be assessed at baseline and Week 8. Functional near-infrared spectroscopy will assess brain activity to explore potential mechanisms. Intervention feasibility, acceptability, and safety will also be evaluated.

02

Conditions studied

  • Cognitive Frailty

Browse trials for

Keywords

  • Virtual Reality
  • Multidomain Intervention
  • Cognitive Function
  • Functional Near-Infrared Spectroscopy
03

In context

Frailty

1,284 studies on the registry are indexed under Frailty; 452 are open to participants now.

This study's planned enrollment of 90 is above the median of 81 across 767 interventional studies indexed under Frailty.

Browse Frailty studies →

Lead sponsor

Zheng Li is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >60 years.
  • FFP score ≥1.
  • ≥24 and either SCD-Q9 ≥5 or MoCA \<26.
  • ADL score ≤26.
  • Ability to follow instructions, communicate discomfort, and safely participate in VR training.
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Dementia, stroke, Parkinson's disease, spinal cord injury, or epilepsy.
  • Medical, psychiatric, or neurological conditions that prevent safe participation.
  • Severe or recurrent vertigo, motion sickness, or intolerance to VR.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Virtual Reality Multidomain Intervention

    Participants will receive supervised virtual reality multidomain training twice weekly for 8 weeks, for a total of 16 sessions. Each session is planned to last approximately 45 minutes, including instruction, warm-up, intermittent VR training, breaks, and task transitions. The program combines cognitive training, physical exercise, nutrition education, and emotional support. Task difficulty and training duration will be adjusted according to individual abilities and tolerance.

    Behavioral: Virtual Reality Multidomain Training

  • Active comparator
    Multidomain Health Education

    Participants will receive multidomain health education covering cognitive health, physical activity, nutrition, and emotional well-being.

    Behavioral: Multidomain Health Education

Interventions

  • BehavioralVirtual Reality Multidomain Training

    A supervised VR program combining cognitive training, physical exercise, nutrition education, and emotional support. Participants attend two sessions weekly for 8 weeks, totaling 16 sessions. Each 45-minute session includes instruction, warm-up, approximately 25 minutes of intermittent VR training, and breaks. VR training includes approximately 10 minutes of cognitive training, 10 minutes of physical exercise, and 5 minutes of nutrition education or emotional support. Nutrition and emotional support activities alternate between the two weekly sessions. VR familiarization is provided before formal training. Task difficulty and training duration are adjusted to individual abilities and tolerance.

  • BehavioralMultidomain Health Education

    Participants will receive multidomain health education covering cognitive health, physical activity, nutrition, and emotional well-being. The educational content addresses the same health domains as the VR intervention.

06

What researchers measure

Primary outcomes

  1. Montreal Cognitive Assessment (MoCA)

    The Montreal Cognitive Assessment (MoCA) will be used to assess cognitive function. Total scores range from 0 to 30, with higher scores indicating better cognitive function.

    Time frame: Baseline and Week 8 (end of intervention)

Secondary outcomes

  1. Short Physical Performance Battery

    The Short Physical Performance Battery (SPPB) will be used to assess lower-extremity physical function through standing balance, walking speed, and repeated chair stands. Total scores range from 0 to 12, with higher scores indicating better physical performance.

    Time frame: Baseline and Week 8 (end of intervention)

  2. Fried Frailty Phenotype

    The Fried Frailty Phenotype (FFP) will be used to assess physical frailty based on five criteria: unintentional weight loss, exhaustion, weakness, slow walking speed, and low physical activity. Total scores range from 0 to 5, with higher scores indicating greater frailty.

    Time frame: Baseline and Week 8 (end of intervention)

  3. Timed Up and Go Test (TUG)

    The Timed Up and Go (TUG) test will be used to assess functional mobility. Participants rise from a chair, walk 3 meters, turn, walk back, and sit down. Completion time is recorded in seconds, with shorter times indicating better functional mobility.

    Time frame: Baseline and Week 8 (end of intervention)

  4. Patient Health Questionnaire-9 (PHQ-9)

    The Patient Health Questionnaire-9 (PHQ-9) will be used to assess depressive symptoms over the preceding two weeks. Total scores range from 0 to 27, with higher scores indicating more severe depressive symptoms.

    Time frame: Baseline and Week 8 (end of intervention)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jun 2027, 7 months later.

Of 513 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 7 months is below that.

Counting every sponsor, half of 517 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2026
First posted
Nov 6, 2026
StartEst.
Nov 3, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07923474
Lead sponsor
Zheng Li
Responsible party
Zheng Li (Professor, Peking Union Medical College) — Sponsor-investigator
First posted
Nov 6, 2026
Start date
Nov 3, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Qian Liu
Contact
shiliuqiana@163.com
+86 13175250076 ext. Master's degre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion